secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001079973-25-000800
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
- Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.
- Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.
- Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.
- Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/0001079973-25-000800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325000800/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-25-000800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer